Gulnara N Rakhimova1, Nasiba U Alimova1, Alexsandr Ryaboshtan1, Boris Waldman2,3, Graham D Ogle2,3,4, Said I Ismailov1. 1. Center for the Scientific and Clinical Study of Endocrinology, Ministry of Health, Tashkent, Uzbekistan. 2. International Diabetes Federation Life for a Child Program, Glebe, Australia. 3. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. 4. Diabetes NSW, Glebe, Australia.
Abstract
AIMS: We aimed to determine the incidence, prevalence and mortality of type 1 diabetes (T1D) in Uzbekistan in children <15 years old. METHODS: In a prospective study from 1998 to 2014 the primary ascertainment of incidence, prevalence and mortality, and cause of death was via data collected by endocrinology dispensaries in Uzbekistan's 14 administrative divisions. A second data collection for 2008-2010 from a national audit in 2011 was used to determine age structure. RESULTS: Over 1998-2014 T1D prevalence roughly doubled (7.8 to 15.3/100,000 population aged <15 years, P = .10), following a doubling of incidence (1.5 to 3.1/100 000 < 15 years), a 5.6% annualized increase, P = .001), with a fall in mortality per 1000 patient years (24.5 to 2.0, P = .001). There was a female preponderance, with a male:female ratio of 0.89 in 2008-2010. In every year, T1D incidence was highest in the 10-14.99 year age-group, although the proportion of diagnoses under 5 years of age increased from 6.0% of total diagnoses in 1998-2002, to 13.4% in 2008-2010. Peak age of onset in 2008-2010 was 13 years. Notable regional variation was evident, with incidence being highest in Tashkent-City (P = .005). The most common cause of death was chronic renal failure-responsible for 31 deaths in children <15 years during the study period. CONCLUSIONS: Our results provide the first long-term epidemiological data for T1D in Uzbekistan and the region. Uzbekistan is country of low but rising T1D incidence and prevalence, and falling mortality. Attention to improving clinical care is warranted, to reduce long-term complications.
AIMS: We aimed to determine the incidence, prevalence and mortality of type 1 diabetes (T1D) in Uzbekistan in children <15 years old. METHODS: In a prospective study from 1998 to 2014 the primary ascertainment of incidence, prevalence and mortality, and cause of death was via data collected by endocrinology dispensaries in Uzbekistan's 14 administrative divisions. A second data collection for 2008-2010 from a national audit in 2011 was used to determine age structure. RESULTS: Over 1998-2014 T1D prevalence roughly doubled (7.8 to 15.3/100,000 population aged <15 years, P = .10), following a doubling of incidence (1.5 to 3.1/100 000 < 15 years), a 5.6% annualized increase, P = .001), with a fall in mortality per 1000 patient years (24.5 to 2.0, P = .001). There was a female preponderance, with a male:female ratio of 0.89 in 2008-2010. In every year, T1D incidence was highest in the 10-14.99 year age-group, although the proportion of diagnoses under 5 years of age increased from 6.0% of total diagnoses in 1998-2002, to 13.4% in 2008-2010. Peak age of onset in 2008-2010 was 13 years. Notable regional variation was evident, with incidence being highest in Tashkent-City (P = .005). The most common cause of death was chronic renal failure-responsible for 31 deaths in children <15 years during the study period. CONCLUSIONS: Our results provide the first long-term epidemiological data for T1D in Uzbekistan and the region. Uzbekistan is country of low but rising T1D incidence and prevalence, and falling mortality. Attention to improving clinical care is warranted, to reduce long-term complications.
Authors: Gunduz Ahmad Ahmadov; Denira Govender; Mark Alvin Atkinson; Rumiyya Anvar Sultanova; Amalia Abdulla Eubova; Clive Henry Wasserfall; Steven John Mack; Julie Ann Lane; Janelle Annette Noble; Graham David Ogle Journal: Diabetes Res Clin Pract Date: 2018-09-13 Impact factor: 5.602
Authors: Paz L D Ruiz; Lei Chen; Jedidiah I Morton; Agus Salim; Bendix Carstensen; Edward W Gregg; Meda E Pavkov; Manel Mata-Cases; Didac Mauricio; Gregory A Nichols; Santa Pildava; Stephanie H Read; Sarah H Wild; Jonathan E Shaw; Dianna J Magliano Journal: Diabetologia Date: 2022-03-22 Impact factor: 10.122